“…Based on the available evidence, MRI-PDFF, MRI-based corrected T1, and parameters as measured by transient elastography (FibroScan, Echosens, Paris, France), namely controlled attenuation parameter (CAP), are most frequently pursued as primary and/or secondary endpoints in randomized clinical trials (RCTs), usually to determine the degree of hepatic fibrosis. Furthermore, Nterminal type III collagen propeptide, enhanced liver fibrosis, and cytokeratin 18 seem to be the most promising biomarkers to assess physiological changes (Siddiqui et al, 2019;Hydes et al, 2021;Andersson et al, 2022;Jincheng Wang et al, 2022) in response to interventional treatment in a phase 2a trial design and may serve as primary and/or secondary endpoints (Ampuero and Romero-Gomez, 2020;Chen et al, 2023)…”